Pfizer and Sangamo enter gene therapy deal | January 8, 2018 Issue - Vol. 96 Issue 2 | Chemical & Engineering News
Volume 96 Issue 2 | p. 10 | Concentrates
Issue Date: January 8, 2018

Pfizer and Sangamo enter gene therapy deal

By Ryan Cross
Department: Business
Keywords: Gene therapy, Sangamo, Pfizer, ALS, neurodegenerative, zinc finger

Drug giant Pfizer will partner with Sangamo Therapeutics to develop a gene therapy for the neurodegenerative disorders amyotrophic lateral sclerosis and frontotemporal lobar degeneration. The therapy will use a zinc finger protein to bind a region of mutant DNA implicated in familial versions of the diseases. When the zinc finger is present, a second protein attached to it shuts down expression of the disease-causing gene. Sangamo will receive $12 million up front and potential milestones of up to $150 million.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment